ACTU Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of --. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat CEL-SCI Corp.'s return on equity of -266.61%.

Actuate Therapeutics, Inc. has a consensus price target of $25.03, signalling upside risk potential of 240.54%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Actuate Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Actuate Therapeutics, Inc..

Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Actuate Therapeutics, Inc.'s net income of -$5.4M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of -953.4%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Actuate Therapeutics, Inc. has a consensus price target of $25.03, signalling upside risk potential of 240.54%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Actuate Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Actuate Therapeutics, Inc..

Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of 33.68%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat Merck & Co., Inc.'s return on equity of 39.63%.

Actuate Therapeutics, Inc. has a consensus price target of $25.03, signalling upside risk potential of 240.54%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Actuate Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Merck & Co., Inc..

Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Soleno Therapeutics, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of 39.4%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat Soleno Therapeutics, Inc.'s return on equity of -26.56%.

Actuate Therapeutics, Inc. has a consensus price target of $25.03, signalling upside risk potential of 240.54%. On the other hand Soleno Therapeutics, Inc. has an analysts' consensus of $113.54 which suggests that it could grow by 121.02%. Given that Actuate Therapeutics, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Soleno Therapeutics, Inc..

Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics, Inc. has a beta of -3.150, suggesting its less volatile than the S&P 500 by 415.022%.

Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. Soleno Therapeutics, Inc. pays out -- of its earnings as a dividend.

Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than Soleno Therapeutics, Inc. quarterly revenues of $66M. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than Soleno Therapeutics, Inc.'s net income of $26M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while Soleno Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 25.45x for Soleno Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.